Search Result

Results for "

transient ischemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) AMPK (2) Amyloid-β (1) Apoptosis (2) Caspase (1) COX (2) Cytochrome P450 (1) Dopamine Receptor (1) Drug Derivative (1) ERK (2) Glutathione Peroxidase (1) Histamine Receptor (1) iGluR (2) Interleukin Related (2) JNK (1) MDM-2/p53 (1) MEK (2) NF-κB (2) NO Synthase (1) Potassium Channel (1) PPAR (2) Reference Standards (1) Sigma Receptor (1) SOD (1) STAT (2) TNF Receptor (2) Wnt (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (6)

By Targets:

Adrenergic Receptor (2)

AMPK (2)

Amyloid-β (1)

Apoptosis (2)

Caspase (1)

COX (2)

Cytochrome P450 (1)

Dopamine Receptor (1)

Drug Derivative (1)

ERK (2)

Glutathione Peroxidase (1)

Histamine Receptor (1)

iGluR (2)

Interleukin Related (2)

JNK (1)

MDM-2/p53 (1)

MEK (2)

NF-κB (2)

NO Synthase (1)

Potassium Channel (1)

PPAR (2)

Reference Standards (1)

Sigma Receptor (1)

SOD (1)

STAT (2)

TNF Receptor (2)

Wnt (2)

By Research Areas:

Cancer (3)

Cardiovascular Disease (2)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (6)

Inhibitors & Agonists

Natural
Products

Targets Recommended: TRP Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0541

Pseudoginsenoside F11 2 Publications Verification Ginsenoside A1	Amyloid-β JNK MDM-2/p53 Caspase SOD Glutathione Peroxidase NO Synthase	Cardiovascular Disease Neurological Disease
Pseudoginsenoside F11 is an orally active neuroprotective agent. Pseudoginsenoside F11 reduces the expression of β-amyloid precursor protein, inhibits the production of Aβ_1-40, downregulates the expression of JNK2, p53 and activated Caspase 3, and restores the activities of SOD and Glutathione peroxidase. Pseudoginsenoside F11 inhibits the excessive activation of μ-Calpain and restores the level of neuronal Nitric oxide synthase. Pseudoginsenoside F11 reduces infarct volume, alleviates cerebral edema, decreases neuronal loss, improves neurological deficits and enhances long-term functional outcomes in transient cerebral ischemia models. Pseudoginsenoside F11 antagonizes Methamphetamine-induced behavioral deficits, dopamine level reduction and neurotoxicity without altering the baseline behaviors of normal mice. Pseudoginsenoside F11 can be used in studies related to Alzheimer's disease, transient cerebral ischemic injury and Methamphetamine-induced neurotoxicity .

HY-101481

Flurbiprofen axetil	COX Apoptosis MEK ERK PPAR AMPK NF-κB Interleukin Related TNF Receptor STAT Wnt	Neurological Disease Inflammation/Immunology Cancer
Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway .

HY-101043

4-PPBP maleate	Sigma Receptor iGluR	Neurological Disease
4-PPBP maleate is a potent σ 1 receptor ligand and agonist. 4-PPBP maleate is a non-competitive, selective NR1a/2B NMDA receptors (expressed in Xenopus oocytes) antagonist. 4-PPBP maleate provides neuroprotection .

HY-148825

NP10679	iGluR Histamine Receptor Potassium Channel Cytochrome P450 Adrenergic Receptor	Metabolic Disease Inflammation/Immunology Cancer
NP10679 is a selective, pH dependent GluN2B subunit-specific N-methyl-D-aspartate (NMDA) receptor inhibitor with high oral bioavailability and good brain penetration. NP10679 inhibits GluN2B with IC₅₀s of 23 and 142 nM at pH 6.9 and 7.6, respectively. NP10679 is a histamine H1 antagonist and a hERG channel inhibitor with IC₅₀s of 73 and 620 nM, respectively. NP10679 is a reversible inhibitor of human liver CYP enzymes .

HY-106865

Mivazerol	Dopamine Receptor Adrenergic Receptor	Cardiovascular Disease
Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research _.

HY-162164

Neuroprotective agent 3	Others	Neurological Disease
Neuroprotective agent 3 (Compound 21a) is an antioxidant that exhibits neuroprotective effects. Neuroprotective agent 3 significantly increases neuronal viability and induces neuroprotection, as well as improves neurological deficit scores in an in vivo model of transient cerebral ischemia .

HY-101481R

Flurbiprofen axetil (Standard)	Reference Standards COX Apoptosis MEK ERK PPAR AMPK NF-κB Interleukin Related TNF Receptor STAT Wnt	Neurological Disease Inflammation/Immunology Cancer
Flurbiprofen axetil (Standard) is the analytical standard of Flurbiprofen axetil. This product is intended for research and analytical applications. Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway .

HY-106366

Siagoside	Drug Derivative	Neurological Disease Inflammation/Immunology
Siagoside is an inner ester of Ganglioside GM1 (HY-N10546). Siagoside selectively attenuates morphological and functional striatal impairments induced by transient forebrain ischemia in rats. Siagoside can be used for the research of neurological disease, such as acute cerebral ischemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0541

Pseudoginsenoside F11 2 Publications Verification Ginsenoside A1	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Other Diseases Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification	Amyloid-β JNK MDM-2/p53 Caspase SOD Glutathione Peroxidase NO Synthase
Pseudoginsenoside F11 is an orally active neuroprotective agent. Pseudoginsenoside F11 reduces the expression of β-amyloid precursor protein, inhibits the production of Aβ_1-40, downregulates the expression of JNK2, p53 and activated Caspase 3, and restores the activities of SOD and Glutathione peroxidase. Pseudoginsenoside F11 inhibits the excessive activation of μ-Calpain and restores the level of neuronal Nitric oxide synthase. Pseudoginsenoside F11 reduces infarct volume, alleviates cerebral edema, decreases neuronal loss, improves neurological deficits and enhances long-term functional outcomes in transient cerebral ischemia models. Pseudoginsenoside F11 antagonizes Methamphetamine-induced behavioral deficits, dopamine level reduction and neurotoxicity without altering the baseline behaviors of normal mice. Pseudoginsenoside F11 can be used in studies related to Alzheimer's disease, transient cerebral ischemic injury and Methamphetamine-induced neurotoxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

transient ischemia

Inhibitors & Agonists

NaturalProducts

Natural
Products